bims-tumhet Biomed News
on Tumor heterogeneity
Issue of 2026–11–15
ten papers selected by
Sergio Marchini, Humanitas Research



  1. Nat Med. 2026 Nov 10.
    Jochen Wilhelm, Amit Kumar, Hitesh Vasiyani, Narsimha Mamidi, Zhaoyu Sun, Aenya Gogna, Praveen Bhoopathi, Keshav C Gogna, Chelsea Salyer, Amy Lu, Kranthi Kumar Chougoni, Ava N Gardner, Andrew S Poklepovic, Masaki Nagane, Kumari S Shree, Emad A Rakha, Karuppaiyah Selvendiran, George L Maxwell, Jamie N Bakkum-Gamez, Shariska Petersen Harrington, Elnaz Abbasi Farid, Nadia Traficante, David Bowtell, Christopher D Collier, Rebecca Z Drexler, Christine Kramer, Mary M Mullen, Alexandar Tzankov, Kirsten D Mertz, Jun Watanabe, Shimpei Nagai, Tatsuyuki Chiyoda, Wataru Yamagami, Kenta Masuda, Elena Garre, Göran Landberg, David L Kolin, Calla O'Connor, Sarah A Ackroyd, Bodour Salhia, Paola A Gehrig, Aanya Singh, Tytus Bernas, Anusha Challa, Sriram Sriperumbuduri, Nolan A Wages, Jordan Lewis, Lien Hoang, Janice S Kwon, Jasmin D Haslbauer, Mark P Kühnel, T Rinda Soong, Sarah Taylor, Carlos Zuazo, Tiffany Beck, Michael J Demeure, Marc R Radke, Sourat Darabi, Denise Connolly, Barbara S Norquist, Nozomi Yachida, Kazuaki Suda, Kosuke Yoshihara, Tu-Yung Chang, Patrick Martin, Kyoung Jae Won, Tian-Li Wang, Ie-Ming Shih, Thomas Russell Pisanic, Tanvir K Dhaliwal, Vandanaa Jayaprakash, Bukola Adeshina, Seungpyo Hong, Ana Blanca, David R Braxton, Cesar M Castro, Elizabeth M Swisher, Allan Tsung, Ernst Lengyel, Susan Domchek, William L Redmond, Yonglun Luo, Ole Mogensen, Robert A Winn, Bo R Rueda, Ronny Drapkin, Andrew K Godwin, Ronald J Buckanovich, Kenneth P Nephew, Rafael J Luque, Antonio Lopez-Beltran, Robert L Coleman, Daniel Von Hoff, David Sidransky, Maximilian Ackermann, Danny Jonigk, Steven R Grossman, Ranjit Manchanda, Rajan Gogna, Esha Madan.
      Flower-Win/Lose signaling underlies a tumor-host fitness conflict in ovarian cancer, in which tumor-derived exosomal Tu-stroma reduces the fitness of surrounding host cells, favoring tumor expansion within host tissues. High-grade serous carcinoma (HGSC), the most prevalent histotype of epithelial ovarian cancer and leading cause of ovarian-cancer-related mortality, arises from serous tubal intraepithelial carcinoma (STIC), a noninvasive precursor typically identifiable only by histopathologic examination of excised fallopian tube tissue. Here we evaluated Tu-stroma, a tumor-associated long noncoding RNA enriched in serum extracellular vesicles (EVs), as a circulating biomarker in STIC and early-stage HGSC, representing the earliest histopathologically defined phases of disease. Tu-stroma was quantified in serum EVs from 506 individuals with histologically normal adnexa, benign-adnexal lesions, isolated STIC and HGSC across International Federation of Gynecology and Obstetrics (FIGO) stages I-IV. Normalized EV Tu-stroma ΔCT values were elevated in STIC (n = 43) and HGSC (n = 232) versus controls (n = 143) and benign-adnexal lesions (n = 88), including premenopausal women (controls = 57, benign = 34, STIC = 32, HGSC = 88). In paired receiver operating characteristic analyses, Tu-stroma showed higher discrimination than cancer antigen 125 (CA125) for STIC versus controls (area under the curve (AUC) = 0.99 versus 0.59, P < 0.001) and benign-adnexal masses (0.99 versus 0.31, P < 0.001), and for HGSC versus controls (AUC = 0.99 versus 0.96, P = 0.001) and benign-adnexal masses (0.98 versus 0.84, P < 0.001). Tu-stroma showed no systematic elevation across inflammatory or physiologic comparators (n = 116) or nonovarian malignancies (n = 160), each assessed against healthy controls (n = 100), supporting disease-context specificity. Modeled risk-enriched contexts yielded predictive values compatible with intended-use populations. These findings identify Tu-stroma as a candidate EV-RNA marker associated with pre-invasive and early HGSC biology. Prospective evaluation in consecutively enrolled real-world cohorts is required to validate diagnostic performance, predictive value and clinical utility.
    DOI:  https://doi.org/10.1038/s41591-026-04732-9
  2. Cancer Res. 2026 Nov 13.
      Epithelial ovarian cancers (EOCs) comprise biologically distinct histotypes that arise within shared anatomical niches where tumor-stroma interactions shape tumor behavior and therapeutic response. However, most classification frameworks rely on bulk profiling that conflates epithelial and stromal contributions, limiting the understanding of crosstalk between the different compartments. Here, we performed compartment-resolved transcriptomic and epigenomic profiling of matched carcinoma and stroma across clear cell (CCOC), endometrioid (ENOC), and high-grade serous ovarian cancers (HGSC). Carcinoma profiles segregated strongly by histotype, whereas stromal profiles showed minimal histotype specificity and instead resolved into four shared groups (S1-S4). The S4 subtype, marked by a desmoplastic, myofibroblast-rich program, was enriched in omental tumors and corresponded to the HGSC C1/Mesenchymal signature. This subtype largely reflected tumor-extrinsic programs and was present beyond HGSC. Compartment-resolved analyses also refined the interpretation of other molecular carcinoma subtypes and revealed distinct carcinoma-intrinsic EMT-like programs. Together, these findings define a histotype-agnostic stromal architecture across epithelial ovarian cancers, clarify the cellular basis of canonical high-grade serous molecular subtypes, and reveal carcinoma-intrinsic EMT programs. This study underscores the value of physically separating epithelial and stromal compartments before molecular analysis and position this dataset as a multi-purpose reference resource for the EOC research community.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-26-1330
  3. Cancer Discov. 2026 Nov 12.
      Early detection of esophageal squamous cell carcinoma (ESCC) is hindered by a lack of noninvasive biomarkers for precancerous lesions. Here, we report a circulating cell-free DNA (cfDNA) methylation approach for early esophageal neoplasia detection. In prospective community screening, the assay achieved standardized sensitivity of 78% at 79% specificity for the clinically actionable endpoint of high-grade intraepithelial neoplasia (HGIN) or ESCC, with stage-specific sensitivities of 76% for HGIN and 86% for ESCC. Genome-wide methylation profiling reveals HGIN as an early epigenetic reprogramming stage. Integrative spatial and single-cell RNA sequencing reveals pronounced remodeling of the endothelial-proximal epithelial cell population, whose methylation signatures are detected in cfDNA. Guided by these findings, we develop an 11-gene cfDNA methylation panel that shows robust discrimination of early-stage ESCC across three retrospective case-control sets and an independent screening-derived case-control set. Together, these results demonstrate that our cfDNA methylation panel has promising utility for early ESCC detection.
    DOI:  https://doi.org/10.1158/2159-8290.CD-26-0691
  4. BMC Cancer. 2026 Aug 15. pii: 1395. [Epub ahead of print]26(1):
       BACKGROUND: Early detection of oral cancer improves outcomes, but remains limited by the invasiveness and low sensitivity of current screening methods.
    METHODS: This study included 342 participants (200 in the training and 142 in the validation cohorts). Plasma cfDNA underwent low-depth whole-genome sequencing, with data normalized to a standardized 5× coverage via down-sampling to ensure consistent analysis. Three cfDNA-derived features, including fragment size ratio (FSR), copy number variation (CNV), and repetitive element profiles (REP), were extracted and integrated using a stacked machine learning ensemble to generate prediction scores. Model performance was evaluated by area under the receiver operating characteristic curve (AUC), sensitivity, and specificity with 95% confidence intervals.
    RESULTS: In the training cohort, oral cancer patients had a median age of 53 years (91% male), while healthy individuals had a median age of 57 years (37% male). In the validation cohort, the median ages were 53 and 57 years, with male proportions of 83.1% and 38.0% in the cancer and healthy groups, respectively. Cancer samples exhibited shorter cfDNA fragments, recurrent CNV gains at 3q and 8q, and losses at 3p and 5q. The individual AUCs for FSR, CNV, and REP were 0.973, 0.983, and 0.979 in the training cohort, and 0.960, 0.982, and 0.972 in the validation cohort, respectively. The integrated stacked model achieved AUCs of 0.996 (95% CI: 0.991-1.000) and 0.988 (95% CI: 0.975-0.988) in the training and validation cohorts, respectively. To prioritize high specificity for large-scale screening, a decision threshold was established in the training cohort to target 98.0% specificity, which yielded a corresponding sensitivity of 98.0%. When this pre-fixed threshold was blindly applied to the independent validation cohort, a sensitivity of 94.4% and a specificity of 95.8% were achieved. Prediction scores were not significantly associated with age, sex, or tumor site.
    CONCLUSIONS: The cfDNA fragmentomics-based stacked model distinguished oral cancer from healthy individuals, including early stage disease, supporting its potential for noninvasive approach for oral cancer detection.
    Keywords:  Cell-free DNA; Early detection; Fragmentomics; Low depth whole genome sequencing; Oral cancer
    DOI:  https://doi.org/10.1186/s12885-026-16606-x
  5. Ann Oncol. 2026 Nov 13. pii: S0923-7534(26)08683-7. [Epub ahead of print]
       BACKGROUND: Detection of circulating tumor DNA (ctDNA) harboring mutations that match those identified in resected tumor tissue signals occult residual disease after curative-intent surgery. Such patients are considered minimal residual disease (MRD)-positive and at high risk for recurrence and death. Few studies have shown that therapeutic intervention can alter recurrence risk in MRD-positive patients. We evaluated whether PD-1 blockade could reduce recurrence in MRD-positive patients with mismatch repair-deficient (dMMR) tumors after curative-intent resection regardless of tumor site of origin.
    PATIENTS AND METHODS: We initiated a prospective phase II interventional study in patients who had undergone curative-intent resection of early-stage dMMR tumors from any anatomic site. Postoperative MRD status was assessed by first identifying those patients who had detectable ctDNA and then confirming the ctDNA relevance to MRD by matching mutations detected in ctDNA to somatic mutations detected in resected tumor tissue. Confirmed MRD-positive patients received 6 months of PD-1 blockade and were evaluated for ctDNA clearance and 24-month recurrence-free survival (RFS). MRD-negative patients underwent observation.
    RESULTS: We screened 184 patients with early-stage dMMR solid tumors after curative resection and tumor sequencing with ctDNA testing for MRD assessment. Twenty-three patients (12.5%) were MRD-positive; after excluding one assigned to placebo and three with synchronous radiographic disease, 19 were eligible. Six developed recurrences before pembrolizumab initiation despite being disease-free at enrollment. The remaining 13 MRD-positive patients received 6 months of PD-1 blockade. ctDNA clearance at 6 months was achieved in 11 of 13 patients (85%). Five treated patients (38%) developed recurrence during follow-up. Median follow-up for the MRD-positive patients was 59 months (95% CI: 52-NR). Among 152 MRD-negative patients managed with observation, 14 (9%) developed recurrence during follow-up; 2-year RFS was 92%.
    CONCLUSIONS: These findings provide evidence that ctDNA-guided adjuvant therapy may offer clinical benefit in dMMR tumors regardless of tissue of origin.
    Keywords:  MSI-high; adjuvant therapy; circulating tumor DNA; dMMR; immune checkpoint blockade; minimal residual disease; tumor agnostic therapy
    DOI:  https://doi.org/10.1016/j.annonc.2026.11.005
  6. Cells. 2026 Nov 03. pii: 2004. [Epub ahead of print]15(21):
      Ovarian cancer is a lethal gynecologic malignancy with limited effective treatment options. It is expected that in 2026 there will be about 21,010 new cases of ovarian cancer diagnosed and about 12,450 deaths within the United States. Unfortunately, conventional therapies such as chemotherapy and radiation have limited efficacy for high-grade serous ovarian cancer (HGSOC) and also produce significant toxicity. HGSOC is characterized by an ovarian tumor microenvironment (TME) consisting of immune inhibitory T regulatory cells and inhibitory tumor-associated macrophages, including myeloid-derived suppressor cells (MDSCs) and M2 cells, which confer immune suppression. Immunocompetent T cells, tumor-suppressing M1 cells, natural killer cells, and other cellular subsets are also present. The TME is further shaped by soluble molecules, extracellular matrix, and other structural components, as well as the presence of blood vessels and ascitic fluid in the peritoneal cavity, which aid in the distribution of cancer cells to the omentum where more lesions soon develop. This review outlines the heterogenous immune cell subsets in the ovarian TME and other structural targets that promote or reduce cancer burden. Most single-agent immune strategies have shown limited efficacy in unselected HGSOC populations due to the complex immune-suppressive nature of the TME. Here, we also discuss novel combination treatments in clinical trials or in clinical practice for HGSOC. Advances in understanding the ovarian TME will reveal new immunotherapy and drug targets for translational medicine and aid in determining effective drug and immunotherapy combinations, which may ultimately lead to improved overall survival in HGSOC.
    Keywords:  T regulatory cells; clinical trials; dendritic cells; macrophages; neutrophils; novel therapies; ovarian cancer; tumor microenvironment
    DOI:  https://doi.org/10.3390/cells15212004
  7. Cancers (Basel). 2026 Oct 23. pii: 3431. [Epub ahead of print]18(21):
      Background: Outcomes for advanced or recurrent endometrial cancer (EC) remain poor, with historically limited systemic options beyond platinum-based chemotherapy. EC is uniquely immunotherapy-amenable among solid tumors: it harbors the highest prevalence of mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) status of any cancer, and its molecular classification into four major molecular subtypes defines a spectrum of tumor mutational burden, neoantigen load, and immune infiltration that predicts the response to checkpoint blockade. Current Landscape: Over the past several years, multiple programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have received regulatory approval in EC, spanning monotherapy in dMMR/MSI-H disease, combination with carboplatin-paclitaxel in the first-line advanced setting, and combination with anti-angiogenic therapy in biomarker-unselected recurrent disease, fundamentally altering the standard of care. Scope and Objectives: This narrative review synthesizes the molecular rationale for checkpoint inhibition in EC, including the biological basis of its molecular subtypes and their immune microenvironments, and provides a focused overview of the trial evidence supporting each major checkpoint inhibitor class, including PD-1 inhibitors, PD-L1 inhibitors, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and emerging targets. We further review the landscape of ongoing trials addressing unresolved questions, including chemotherapy-free regimens in dMMR disease, maintenance intensification for mismatch repair-proficient (pMMR) disease, neoadjuvant and fertility-sparing approaches, and novel combinations. This review aims to provide a comprehensive, up-to-date synthesis of this rapidly evolving field and to identify challenges and opportunities that will shape the next phase of immunotherapy in EC.
    Keywords:  CTLA-4; PD-1; PD-L1; endometrial cancer; immune checkpoint inhibitors; immunotherapy; microsatellite instability; mismatch repair deficiency; molecular classification; tumor microenvironment
    DOI:  https://doi.org/10.3390/cancers18213431
  8. Transl Cancer Res. 2026 Oct 30. 15(10): 727
      
    Keywords:  Ovarian cancer; Poly(ADP-ribose) polymerase inhibitor (PARP inhibitor); maintenance therapy; post-progression survival; rucaparib
    DOI:  https://doi.org/10.21037/tcr-2026-2329
  9. Clin Cancer Res. 2026 Nov 09.
      BRCA1 has long been recognized as a guardian of genome integrity through its essential role in homologous recombination (HR)-mediated DNA repair. While HR deficiency underlies the clinical efficacy of Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), therapeutic responses remain incomplete, highlighting the need to identify vulnerabilities beyond defective DNA repair. Recent evidence has expanded the biological landscape of BRCA1, revealing critical roles in mitochondrial (mt) quality control, metabolic homeostasis, redox regulation, and innate immune signaling. Together, these functions support an integrated genome-mitochondria-immune axis through which BRCA1 coordinates cellular adaptation to stress. Disruption of this network amplifies genomic instability, promotes metabolic rewiring and inflammatory signaling, and generates vulnerabilities extending beyond HR deficiency. Mitochondrial dysfunction resulting from BRCA1 loss reinforces tumor progression through mitochondrial DNA (mtDNA) instability, oxidative stress, and tumor microenvironment remodeling while creating opportunities for therapeutic intervention. Viewing BRCA1 deficiency through this integrated framework broadens the concept of synthetic lethality and provides a rationale for combination strategies integrating PARP inhibition with mitochondrial-targeted agents, metabolic therapies, epigenetic modulators, and immune-based approaches. This perspective positions BRCA1 as a central regulator of nuclear-mitochondrial crosstalk and highlights emerging opportunities to overcome therapeutic resistance and advance precision oncology.
    DOI:  https://doi.org/10.1158/1078-0432.CCR-26-2385
  10. Nature. 2026 Nov 11.
      Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis1-3. Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival4-7. Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling. Direct comparison of single-cell proteomic and genomic profiling of monomethylation and trimethylation of histone 3 on lysine 4 revealed that these marks are key features associated with loss of luminal identity. Finally, we highlight the potential of concomitant single-molecule profiling of histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis of breast cancer. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, which enables the identification of patients at increased risk for disease relapse.
    DOI:  https://doi.org/10.1038/s41586-026-11230-y